IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0114339.html
   My bibliography  Save this article

Modeling Test and Treatment Strategies for Presymptomatic Alzheimer Disease

Author

Listed:
  • James F Burke
  • Kenneth M Langa
  • Rodney A Hayward
  • Roger L Albin

Abstract

Objectives: In this study, we developed a model of presymptomatic treatment of Alzheimer disease (AD) after a screening diagnostic evaluation and explored the circumstances required for an AD prevention treatment to produce aggregate net population benefit. Methods: Monte Carlo simulation methods were used to estimate outcomes in a simulated population derived from data on AD incidence and mortality. A wide variety of treatment parameters were explored. Net population benefit was estimated in aggregated QALYs. Sensitivity analyses were performed by individually varying the primary parameters. Findings: In the base-case scenario, treatment effects were uniformly positive, and net benefits increased with increasing age at screening. A highly efficacious treatment (i.e. relative risk 0.6) modeled in the base-case is estimated to save 20 QALYs per 1000 patients screened and 221 QALYs per 1000 patients treated. Conclusions: Highly efficacious presymptomatic screen and treat strategies for AD are likely to produce substantial aggregate population benefits that are likely greater than the benefits of aspirin in primary prevention of moderate risk cardiovascular disease (28 QALYS per 1000 patients treated), even in the context of an imperfect treatment delivery environment.

Suggested Citation

  • James F Burke & Kenneth M Langa & Rodney A Hayward & Roger L Albin, 2014. "Modeling Test and Treatment Strategies for Presymptomatic Alzheimer Disease," PLOS ONE, Public Library of Science, vol. 9(12), pages 1-20, December.
    • Handle: RePEc:plo:pone00:0114339
    DOI: 10.1371/journal.pone.0114339
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0114339
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0114339&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0114339?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Bas Groot Koerkamp & Milton C. Weinstein & Theo Stijnen & M.H. Heijenbrok-Kal & M.G. Myriam Hunink, 2010. "Uncertainty and Patient Heterogeneity in Medical Decision Models," Medical Decision Making, , vol. 30(2), pages 194-205, March.
    2. Dennis G. Fryback & Erik J. Dasbach & Ronald Klein & Barbara E.K. Klein & Norma Dorn & Kathy Peterson & Patrica A. Martin, 1993. "The Beaver Dam Health Outcomes study," Medical Decision Making, , vol. 13(2), pages 89-102, June.
    3. Brookmeyer, R. & Gray, S. & Kawas, C., 1998. "Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset," American Journal of Public Health, American Public Health Association, vol. 88(9), pages 1337-1342.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hirsch Ruchlin & Ralph Insinga, 2008. "A Review of Health-Utility Data for Osteoarthritis," PharmacoEconomics, Springer, vol. 26(11), pages 925-935, November.
    2. Louis S. Matza & Katherine J. Kim & Holly Yu & Katherine A. Belden & Antonia F. Chen & Mark Kurd & Bruce Y. Lee & Jason Webb, 2019. "Health state utilities associated with post-surgical Staphylococcus aureus infections," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 819-827, August.
    3. Stavros Petrou & Christine Hockley, 2005. "An investigation into the empirical validity of the EQ‐5D and SF‐6D based on hypothetical preferences in a general population," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1169-1189, November.
    4. Don Kenkel, 2006. "WTP- and QALY-Based Approaches to Valuing Health for Policy: Common Ground and Disputed Territory," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 34(3), pages 419-437, July.
    5. Jamal B. Williams & Qing Cao & Wei Wang & Young-Ho Lee & Luye Qin & Ping Zhong & Yong Ren & Kaijie Ma & Zhen Yan, 2023. "Inhibition of histone methyltransferase Smyd3 rescues NMDAR and cognitive deficits in a tauopathy mouse model," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    6. Zarish Noreen & Jessica DeJesus & Attya Bhatti & Christopher A. Loffredo & Peter John & Jahangir S. Khan & Gail Nunlee-Bland & Somiranjan Ghosh, 2018. "Epidemiological Investigation of Type 2 Diabetes and Alzheimer’s Disease in a Pakistani Population," IJERPH, MDPI, vol. 15(8), pages 1-10, July.
    7. Joshua T. Cohen & John D. Graham, 2003. "A Revised Economic Analysis of Restrictions on the Use of Cell Phones While Driving," Risk Analysis, John Wiley & Sons, vol. 23(1), pages 5-17, February.
    8. John Anderson & Robert Kaplan & Christopher Ake, 2004. "Arthritis Impact on U.S. Life Quality: Morbidity and Mortality Effects From National Health Interview Survey Data 1986–1988 and 1994 Using QWBX1 Estimates of Well-Being," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 69(1), pages 67-91, October.
    9. Masataka Kikuchi & Soichi Ogishima & Tadashi Miyamoto & Akinori Miyashita & Ryozo Kuwano & Jun Nakaya & Hiroshi Tanaka, 2013. "Identification of Unstable Network Modules Reveals Disease Modules Associated with the Progression of Alzheimer’s Disease," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-1, November.
    10. Costa-Font, Montserrat & Costa-Font, Joan, 2009. "Heterogeneous 'adaptation' and 'income effects' across self-reported health distribution?," Journal of Behavioral and Experimental Economics (formerly The Journal of Socio-Economics), Elsevier, vol. 38(4), pages 574-580, August.
    11. Beate Jahn & Sarah Friedrich & Joachim Behnke & Joachim Engel & Ursula Garczarek & Ralf Münnich & Markus Pauly & Adalbert Wilhelm & Olaf Wolkenhauer & Markus Zwick & Uwe Siebert & Tim Friede, 2022. "On the role of data, statistics and decisions in a pandemic," AStA Advances in Statistical Analysis, Springer;German Statistical Society, vol. 106(3), pages 349-382, September.
    12. Harris, Ryan A. & Nease, Robert Jr., 1997. "The importance of patient preferences for comorbidities in cost-effectiveness analyses," Journal of Health Economics, Elsevier, vol. 16(1), pages 113-119, February.
    13. Kibum Kim & Gwendolyn A McMillin & Philip S Bernard & Srinivas Tantravahi & Brandon S Walker & Robert L Schmidt, 2019. "Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-21, December.
    14. Joyce H S You & Kia K N Tsui & Raymond S M Wong & Gergory Cheng, 2012. "Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation," PLOS ONE, Public Library of Science, vol. 7(6), pages 1-9, June.
    15. Patricia Vold Pepper & Douglas K. Owens, 2002. "Cost-Effectiveness of the Pneumococcal Vaccine in Healthy Younger Adults," Medical Decision Making, , vol. 22(1_suppl), pages 45-57, September.
    16. Hans-Helmut König & Oliver Günther & Matthias Angermeyer & Christiane Roick, 2009. "Utility Assessment in Patients with Mental Disorders," PharmacoEconomics, Springer, vol. 27(5), pages 405-419, May.
    17. Maarten Ijzerman & Lotte Steuten, 2011. "Early assessment of medical technologies to inform product development and market access," Applied Health Economics and Health Policy, Springer, vol. 9(5), pages 331-347, September.
    18. Pierre Joly & Célia Touraine & Aurore Georget & Jean-François Dartigues & Daniel Commenges & Hélène Jacqmin-Gadda, 2013. "Prevalence Projections of Chronic Diseases and Impact of Public Health Intervention," Biometrics, The International Biometric Society, vol. 69(1), pages 109-117, March.
    19. Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette, 2006. "Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada," PharmacoEconomics, Springer, vol. 24(8), pages 815-830, August.
    20. William M Reichmann & Jeffrey N Katz & Elena Losina, 2011. "Differences in Self-Reported Health in the Osteoarthritis Initiative (OAI) and Third National Health and Nutrition Examination Survey (NHANES-III)," PLOS ONE, Public Library of Science, vol. 6(2), pages 1-7, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0114339. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.